ACXP
Acurx Pharmaceuticals, Inc.3.5900
-0.1000-2.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.49MP/E (TTM)
-Basic EPS (TTM)
-8.18Dividend Yield
0%Recent Filings
10-K
FY2025 results
Acurx Pharmaceuticals, a clinical-stage biopharma, reported FY2025 ended December 31, 2025 with no revenue as expected, burning cash on R&D for its lead antibiotic ibezapolstat targeting C. difficile infections. Phase 2 trials wrapped in Q4 2023 with 96% clinical cure rate across 26 patients, far exceeding vancomycin's historical 81%, while preserving beneficial gut microbiome—yet no Q4 2025 financials disclosed in the 10-K. Cash position supports Phase 3 push, but funding remains critical. No buybacks or dividends. Seeking partners amid Nasdaq compliance risks. Delays in Phase 3 enrollment could stall momentum.
8-K
Exec pay cuts, rCDI trial launch
Acurx Pharmaceuticals announced on March 9, 2026, a voluntary 10% base salary cut for top executives—CEO David Luci, Executive Chairman Robert DeLuccia, and CFO Robert Shawah—effective April 1, alongside matching director cash reductions, signaling cost discipline amid tight markets. Leadership simultaneously launched an ibezapolstat open-label pilot trial in up to 20 multiply-recurrent CDI patients, with start-up this month and first enrollment in Q4 2026 to shape a Phase 3 rCDI study targeting FDA LPAD approval. Cash conservation aids trial funding. Forward-looking timelines carry clinical risks.
10-Q
Q3 FY2025 results
Acurx trimmed its Q3 operating loss to $2.0M from $2.8M y/y, as R&D expenses plunged 64% to $0.4M amid lighter Phase 3 prep, while G&A held steady near $1.6M; nine-month net loss improved 44% to $6.4M (diluted EPS $(5.01) on 1.3M shares). Cash swelled to $5.9M on $7.8M from equity raises via direct offerings, ELOC, and warrant exercises, funding burn of $5.6M from ops (no capex disclosed). No debt weighs the balance sheet. Reverse split steadied Nasdaq listing. Clinical delays remain the key hurdle.
8-K
Stockholders approve warrant exercise, share increase
Acurx Pharmaceuticals stockholders approved the issuance of shares underlying Series G-2 warrants at the September 16, 2025 special meeting, securing Nasdaq compliance under Listing Rule 5635(d) with 8.8 million votes in favor amid 9.8 million broker non-votes. They also greenlit increasing authorized common stock from 200 million to 250 million shares, passing 16.5 million to 2.5 million. This bolsters capital flexibility. Yet dilution looms for existing holders.
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
ANNX
Annexon, Inc.
4.80-0.11
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RXRX
Recursion Pharmaceuticals, Inc.
4.20+0.00
VINC
Vincerx Pharma, Inc.
0.01+0.00
XCUR
Exicure, Inc.
6.06+0.33